Pharmacogenomics can enhance patient care by enabling treatments tailored to genetic
make-up and lowering risk of serious adverse events. As of June 2019, there are 132 …

Pharmacogenomics (PGx) studies the use of genetic data to optimize drug therapy.
Numerous clinical centers have commenced implementing pharmacogenetic tests in clinical …

Background There are no pharmacokinetic data of single low dose primaquine (SLDPQ) as
transmission blocking in African children with acute Plasmodium falciparum and glucose-6 …

Background/Objectives: Research on pharmacogenetic variability in response to prescribed
drugs and across ethnic groups is essential for personalized medicine, particularly in …

The US FDA has granted market approval for the first pharmacogenetic test using a DNA
microarray, the AmpliChip CYP450, which genotypes cytochrome P450 (CYP) 2D6 and …

CYP2D6 genotype and debrisoquine metabolic ratio (MR) were analyzed in 133
Nicaraguan Mestizos (NMs) and 260 Cubans divided into Cuban Mestizos (CMs) and White …

Abstract Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier
for the goal of global precision medicine. The RIBEF-CEIBA Network Consortium was …

Introduction: Opioid deprescription is the process of supervised tapering and safe
withdrawal when a potentially inappropriate use is detected. This represents a challenge in …

Debrisoquine hydroxylation polymorphism is by far the most thoroughly studied genetic
polymorphism of the CYP2D6 drug-metabolizing enzyme. Debrisoquine hydroxylation …

Objectives: Our group has previously show that interindividual variability in CYP2D6
hydroxylation capacity was related to personality differences in cognitive social anxiety …